Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Mesothelioma|Glioblastoma|Renal Cell Carcinoma|Non Small Cell Lung Cancer|Melanoma|Pancreatic Ductal Adenocarcinoma|Gastric Cancer|Squamous Cell Carcinoma of Head and Neck|Cholangiocarcinoma|Breast Cancer|Ovarian Cancer|Cervical Cancer|Endocervical Cancer|Colorectal Cancer|Esophageal Cancer
Interventions: DRUG: NGM707|DRUG: NGM707 plus pembrolizumab|DRUG: NGM707|DRUG: NGM707|DRUG: NGM707|DRUG: NGM707 plus pembrolizumab|DRUG: NGM707 plus pembrolizumab
Sponsor: NGM Biopharmaceuticals, Inc
Collaborators: Merck Sharp & Dohme LLC